PMID- 25323082
OWN - NLM
STAT- MEDLINE
DCOM- 20150727
LR  - 20181202
IS  - 1878-6448 (Electronic)
IS  - 1053-8135 (Linking)
VI  - 35
IP  - 4
DP  - 2014
TI  - Effects of propofol-dexmedetomidine combination on ischemia reperfusion-induced 
      cerebral injury.
PG  - 825-34
LID - 10.3233/NRE-141177 [doi]
AB  - BACKGROUND: Due to the lack of efficient neuroprotective therapies, the 
      ischemia-reperfusion (I/R) injury is a major medical problem urgently needed to 
      be further studied. OBJECTIVE: To investigate the neuro-protective effects of 
      propofol-dexmedetomidine (dex) combination on I/R-induced cerebral injury and 
      potential mechanisms. METHODS: Sprague-Dawley rats were randomized to 
      sham-operated, I/R, I/R plus propofol, I/R plus dex, and I/R plus propofol-dex 
      combination group. I/R insult was induced by 2 h middle cerebral artery occlusion 
      (MCAO) followed by 24 h reperfusion; Drugs were administered 20 min before the 
      onset of ischemia and continued for another 2 h. Functional outcomes, the 
      expression of Superoxide dismutase (SOD), Methane Dicarboxylic Aldehyde (MDA), 
      Tumor necrosis factor-alpha (TNF-alpha), Interleukin-1beta (IL-1beta), caspase-3 and protein 
      kinase B (AKT) were tested. RESULTS: Propofol-dex combination significantly 
      mitigates I/R-induced neurological deficits in model rats compared to dex or 
      propofol infusion alone. The decreased activity of SOD was significantly reversed 
      following co-administration of propofol and dex, along with the down-regulated 
      MDA content. Perioperative treatment with propofol and dex significantly 
      suppressed I/R-up regulated TNF-alpha and IL-1beta expressions, ameliorated AKT1 
      expression and caspase-3 activity. CONCLUSION: Propofol-dex combination exerted a 
      stronger neuro-protection against I/R injury when compared with propofol or dex 
      alone.
FAU - Wang, Zhun
AU  - Wang Z
AD  - Department of Anesthesiology, Tianjin First Center Hospital, Tianjin, China.
FAU - Kou, Dangpei
AU  - Kou D
AD  - Department of Anesthesiology, Tianjin Chest Hospital, Tianjin, China.
FAU - Li, Zhaoduan
AU  - Li Z
AD  - Department of Anesthesiology, Tianjin Nankai Hospital, Tianjin, China.
FAU - He, Yongjin
AU  - He Y
AD  - Department of Anesthesiology, Tianjin First Center Hospital, Tianjin, China.
FAU - Yu, Wenli
AU  - Yu W
AD  - Department of Anesthesiology, Tianjin First Center Hospital, Tianjin, China.
FAU - Du, Hongyin
AU  - Du H
AD  - Department of Anesthesiology, Tianjin First Center Hospital, Tianjin, China.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - NeuroRehabilitation
JT  - NeuroRehabilitation
JID - 9113791
RN  - 67VB76HONO (Dexmedetomidine)
RN  - YI7VU623SF (Propofol)
SB  - IM
MH  - Animals
MH  - Dexmedetomidine/administration & dosage/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Infarction, Middle Cerebral Artery/*drug therapy
MH  - Male
MH  - Propofol/administration & dosage/*therapeutic use
MH  - Rats
MH  - Rats, Sprague-Dawley
OTO - NOTNLM
OT  - Propofol-dexmedetomidine combination
OT  - anti-apoptosis
OT  - anti-inflammatory
OT  - antioxidant
OT  - cerebral ischemia reperfusion injury
OT  - neuroprotection
EDAT- 2014/10/18 06:00
MHDA- 2015/07/28 06:00
CRDT- 2014/10/18 06:00
PHST- 2014/10/18 06:00 [entrez]
PHST- 2014/10/18 06:00 [pubmed]
PHST- 2015/07/28 06:00 [medline]
AID - VX124732NK4H0880 [pii]
AID - 10.3233/NRE-141177 [doi]
PST - ppublish
SO  - NeuroRehabilitation. 2014;35(4):825-34. doi: 10.3233/NRE-141177.